
Sandoz, Bio-Thera Solutions Enter Deal to Commercialize Avastin Biosimilar
Bio-Thera Solutions and Sandoz have partnered for to allow for the commercialization of BAT1706, a bevacizumab biosimilar referencing Avastin, for the treatment of several forms of cancer.
Chinese biosimilar maker Bio-Thera Solutions has signed a commercialization and license agreement with Germany–based Sandoz to commercialize BAT1706, a bevacizumab
Bevacizumab is a monoclonal antibody that acts as an inhibitor for vascular endothelial growth factor used to treat several forms of
“Bio-Thera Solutions is happy to enter this agreement with a global biosimilar leader to bring BAT1706, our bevacizumab biosimilar, to patients around the world….Biosimilars are an important aspect of Bio-Thera Solutions corporate strategy and a critical to increasing patient access to innovative products like bevacizumab,” said Shengfeng Li, PhD, CEO of Bio-Thera, in a company
Under the agreement, Bio-Thera will be responsible for development and manufacturing of BAT1706. Sandoz will possess the commercialization rights for the United States, the European Union, Canada, and a select list of other countries.
Additionally, Bio-Thera will receive an upfront payment followed by subsequent milestone payments and is entitled to receive profit share payments in the territories Sandoz will be marketing the product in, according to a
More on BAT1706 and Bio-Thera
Bio-Thera
In addition to BAT1706, Bio-Thera is running a
Bio-Thera began a
In January 2020, Bio-Thera
More on Sandoz’ Biosimilar Products
In May 2021, Sandoz began a
Sandoz’ Canada division has also launched 5 biosimilars on the Canadian market, including
Pegfilgrastim (reference product, Neulasta; Amgen) is used as a prophylaxis for febrile neutropenia in patients with cancer undergoing chemotherapy and rituximab (reference product, Rituxan; Genentech) is used for the treatment of patients with non-Hodgkin
Omnitrope, which references Serostim, is used in patients with growth hormone deficiencies, and although the product is marketed in the United States, it is not considered a biosimilar because it was approved prior to the existence of a biosimilar approval pathway. Erelzi, which references Enbrel, is used to treat
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.